vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Claritev Corp (CTEV). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $246.6M, roughly 2.0× Claritev Corp). CLOVER HEALTH INVESTMENTS, CORP. runs the higher net margin — -10.1% vs -32.7%, a 22.6% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 6.2%). Claritev Corp produced more free cash flow last quarter ($36.4M vs $-69.0M). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 2.5%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

CLOV vs CTEV — Head-to-Head

Bigger by revenue
CLOV
CLOV
2.0× larger
CLOV
$487.7M
$246.6M
CTEV
Growing faster (revenue YoY)
CLOV
CLOV
+38.5% gap
CLOV
44.7%
6.2%
CTEV
Higher net margin
CLOV
CLOV
22.6% more per $
CLOV
-10.1%
-32.7%
CTEV
More free cash flow
CTEV
CTEV
$105.4M more FCF
CTEV
$36.4M
$-69.0M
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
2.5%
CTEV

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
CTEV
CTEV
Revenue
$487.7M
$246.6M
Net Profit
$-49.3M
$-80.6M
Gross Margin
Operating Margin
-10.1%
-3.1%
Net Margin
-10.1%
-32.7%
Revenue YoY
44.7%
6.2%
Net Profit YoY
-123.2%
41.6%
EPS (diluted)
$-4.88

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
CTEV
CTEV
Q4 25
$487.7M
$246.6M
Q3 25
$496.6M
$246.0M
Q2 25
$477.6M
$241.6M
Q1 25
$462.3M
$231.3M
Q4 24
$337.0M
$232.1M
Q3 24
$331.0M
$230.5M
Q2 24
$356.3M
$233.5M
Q1 24
$346.9M
$234.5M
Net Profit
CLOV
CLOV
CTEV
CTEV
Q4 25
$-49.3M
$-80.6M
Q3 25
$-24.4M
$-69.8M
Q2 25
$-10.6M
$-62.6M
Q1 25
$-1.3M
$-71.3M
Q4 24
$-22.1M
$-138.0M
Q3 24
$-9.2M
$-391.4M
Q2 24
$7.4M
$-576.7M
Q1 24
$-19.2M
$-539.7M
Gross Margin
CLOV
CLOV
CTEV
CTEV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
24.5%
Q2 24
30.3%
Q1 24
23.6%
Operating Margin
CLOV
CLOV
CTEV
CTEV
Q4 25
-10.1%
-3.1%
Q3 25
-4.9%
4.1%
Q2 25
-2.2%
6.9%
Q1 25
-0.3%
4.2%
Q4 24
-6.4%
-17.8%
Q3 24
-2.7%
-146.7%
Q2 24
2.0%
-224.4%
Q1 24
-6.5%
-207.4%
Net Margin
CLOV
CLOV
CTEV
CTEV
Q4 25
-10.1%
-32.7%
Q3 25
-4.9%
-28.4%
Q2 25
-2.2%
-25.9%
Q1 25
-0.3%
-30.8%
Q4 24
-6.6%
-59.4%
Q3 24
-2.8%
-169.8%
Q2 24
2.1%
-247.0%
Q1 24
-5.5%
-230.1%
EPS (diluted)
CLOV
CLOV
CTEV
CTEV
Q4 25
$-4.88
Q3 25
$-4.23
Q2 25
$-3.81
Q1 25
$-4.38
Q4 24
$-8.49
Q3 24
$-24.25
Q2 24
$-35.78
Q1 24
$-33.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
CTEV
CTEV
Cash + ST InvestmentsLiquidity on hand
$78.3M
$16.8M
Total DebtLower is stronger
$4.6B
Stockholders' EquityBook value
$308.7M
$-173.9M
Total Assets
$541.0M
$4.9B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
CTEV
CTEV
Q4 25
$78.3M
$16.8M
Q3 25
$39.2M
Q2 25
$56.4M
Q1 25
$23.1M
Q4 24
$194.5M
$16.8M
Q3 24
$288.0M
$86.6M
Q2 24
$254.8M
$48.8M
Q1 24
$208.3M
$58.7M
Total Debt
CLOV
CLOV
CTEV
CTEV
Q4 25
$4.6B
Q3 25
$4.5B
Q2 25
$4.5B
Q1 25
$4.5B
Q4 24
$4.5B
Q3 24
$4.5B
Q2 24
$4.5B
Q1 24
$4.5B
Stockholders' Equity
CLOV
CLOV
CTEV
CTEV
Q4 25
$308.7M
$-173.9M
Q3 25
$340.9M
$-101.8M
Q2 25
$344.2M
$-39.9M
Q1 25
$336.1M
$14.8M
Q4 24
$341.1M
$84.0M
Q3 24
$342.2M
$207.6M
Q2 24
$324.9M
$603.4M
Q1 24
$292.5M
$1.2B
Total Assets
CLOV
CLOV
CTEV
CTEV
Q4 25
$541.0M
$4.9B
Q3 25
$559.7M
$5.0B
Q2 25
$575.0M
$5.1B
Q1 25
$583.7M
$5.1B
Q4 24
$580.7M
$5.2B
Q3 24
$653.0M
$5.3B
Q2 24
$674.2M
$5.7B
Q1 24
$671.8M
$6.4B
Debt / Equity
CLOV
CLOV
CTEV
CTEV
Q4 25
Q3 25
Q2 25
Q1 25
304.87×
Q4 24
53.67×
Q3 24
21.73×
Q2 24
7.48×
Q1 24
3.85×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
CTEV
CTEV
Operating Cash FlowLast quarter
$-66.9M
$66.3M
Free Cash FlowOCF − Capex
$-69.0M
$36.4M
FCF MarginFCF / Revenue
-14.1%
14.8%
Capex IntensityCapex / Revenue
0.4%
12.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-69.2M
$-12.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
CTEV
CTEV
Q4 25
$-66.9M
$66.3M
Q3 25
$12.1M
$19.9M
Q2 25
$5.4M
$61.2M
Q1 25
$-16.3M
$-30.1M
Q4 24
$34.8M
$-33.4M
Q3 24
$50.0M
$72.8M
Q2 24
$44.8M
$18.5M
Q1 24
$25.9M
$49.7M
Free Cash Flow
CLOV
CLOV
CTEV
CTEV
Q4 25
$-69.0M
$36.4M
Q3 25
$11.4M
$-16.3M
Q2 25
$4.8M
$36.6M
Q1 25
$-16.5M
$-68.9M
Q4 24
$33.3M
$-63.8M
Q3 24
$49.6M
$41.1M
Q2 24
$44.4M
$-7.0M
Q1 24
$25.5M
$19.2M
FCF Margin
CLOV
CLOV
CTEV
CTEV
Q4 25
-14.1%
14.8%
Q3 25
2.3%
-6.6%
Q2 25
1.0%
15.2%
Q1 25
-3.6%
-29.8%
Q4 24
9.9%
-27.5%
Q3 24
15.0%
17.8%
Q2 24
12.5%
-3.0%
Q1 24
7.3%
8.2%
Capex Intensity
CLOV
CLOV
CTEV
CTEV
Q4 25
0.4%
12.1%
Q3 25
0.1%
14.7%
Q2 25
0.1%
10.2%
Q1 25
0.0%
16.8%
Q4 24
0.5%
13.1%
Q3 24
0.1%
13.8%
Q2 24
0.1%
10.9%
Q1 24
0.1%
13.0%
Cash Conversion
CLOV
CLOV
CTEV
CTEV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
6.04×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons